Sinopharm WIBP COVID-19 vaccine

The vaccine is given by intramuscular injection. The administered is 2 doses in 3 weeks. Efficacy In May 2021, peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). 12,743 people received the vaccine and 12,737 people received the placebo in these trials. == Manufacturing ==

In June 2021, a new factory started production with the capacity to manufacture 1 billion doses annually. == History ==

In April 2020, China approved clinical trials for a candidate COVID-19 vaccine developed by Sinopharm's Beijing Institute of Biological Products (BIBP) and the Wuhan Institute of Biological Products (WIBP). Clinical trials In March 2021, Cayetano Heredia University running the BIBP and WIBP trials in Peru announced they were seeking to suspend and unblind participants in the WIBP trials for lower efficacy and offer the participants the BIBP vaccine instead, which was showing efficacy. Authorizations On February 25, 2021, China approved the vaccine for general use. According to The New York Times, the vaccine is only approved for limited use in United Arab Emirates. On August 19, 2021, the Philippines approved the vaccine for emergency use authorization. == References ==